Jakafi 10 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FFCA6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $50,653
Award facts
- Contract value 100% obligated
- $50,653.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $50,653.12 to DMS Pharmaceutical Group Inc. for JAKAFI (ruxolitinib) 10 mg tablets on February 4, 2026, with completion scheduled for February 5, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, received this award without set-aside designation, competing on an unrestricted basis. The delivery order falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical support to Department of Defense healthcare facilities worldwide.
The PPV-G GEN V contract, designated as SPE2DR and awarded in November 2025, carries a ceiling value of $499.9 million and extends through December 31, 2036, with a 30-month base period followed by three optional 30-month periods. Under this strategic framework, DMS Pharmaceutical Group is positioned as a critical regional prime vendor contractor authorized to supply branded and generic prescription medications, biologics, vaccines, over-the-counter drugs, and medical consumables to support military medical operations globally. The current delivery order for JAKAFI, a therapeutic agent used in the treatment of certain blood disorders and other conditions, exemplifies the specialized pharmaceutical requirements fulfilled through this arrangement.
Quick answers
Who was awarded contract SPE2DR26FFCA6?
SPE2DR26FFCA6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26FFCA6 worth?
The government has obligated $50,653 on SPE2DR26FFCA6.
Is contract SPE2DR26FFCA6 an order under another contract?
Yes. SPE2DR26FFCA6 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFCA6 competed?
The extent of competition for SPE2DR26FFCA6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award